Full Spectrum CBD Dosing for Dogs and Cats: A Simple Guide to Portion Control and Effects

Solventless Central | Simple Guide to Portion Control | Blog

Maximio Cruze |

Full spectrum CBD dosing guide for dogs and cats

Full Spectrum CBD Dosing for Dogs and Cats: A Simple Guide to Portion Control and Effects

The Dose Is the Variable Most People Get Wrong

Full spectrum CBD fails in dogs and cats for one reason more than any other: the dose never reaches the therapeutic threshold. Not because the product is poor quality. Because the label gives a range, the owner picks a number, and that number is usually too conservative to produce a measurable result.

The peer-reviewed canine literature is specific. Consistent therapeutic response across conditions, including pain, inflammation, anxiety, and seizure frequency, occurs between 2mg/kg and 4mg/kg administered twice daily.[1][2] Below that floor, plasma concentration never reaches the level required to modulate the endocannabinoid receptors driving the symptom. Above the ceiling, adverse events begin to appear in safety literature, though the margin is wide.[7]

2.9mg/kg sits above the efficacy floor, accounts for individual variation in CYP450 enzyme clearance rates between animals, and takes advantage of the CBDA bioavailability premium that solventless extraction preserves. CBDA reaches peak plasma concentration 3.4 times higher than CBD isolate at equivalent labeled doses.[5] That figure is a calculated position within a documented therapeutic window, and it is where the dosing chart below is anchored.

What the Clinical Trials Actually Show

The 2018 Cornell University trial remains the foundational canine dosing benchmark. At 2mg/kg twice daily, 80% of dogs with osteoarthritis showed significant improvement in pain scores and mobility within four weeks, with no serious adverse events.[1] That trial used a full spectrum hemp extract and established the lower boundary of the effective dose range.

A 2026 randomized controlled trial published in Animals titrated dogs with chronic osteoarthritis up to 2mg/kg using a full spectrum RSO extract standardized on CBDA, CBD, THCA, and THC content.[2] Significant analgesic response appeared between 1.5mg/kg and 2mg/kg, with the 24.6% CBDA content of the extract identified as a contributing factor. The titration protocol, ten escalating steps over 30 days, is the clinical model for how dose increases should be managed in practice.

The seizure literature pushes the effective range higher. At 2.5mg/kg twice daily, 89% of dogs with drug-resistant epilepsy experienced reduced seizure frequency, with a median monthly reduction of 33%.[3] Neurological conditions require higher cannabinoid plasma concentrations than musculoskeletal ones, a pharmacological principle consistent across the dataset.

A 2025 systematic review of four canine osteoarthritis trials confirmed the pattern: full spectrum multi-cannabinoid formulations produced significant positive outcomes in three of four studies, while isolate formulations produced the weakest effect profiles across the dataset.[4]

Dosing by Weight and Discomfort Level

The chart below reflects weight-based dosing across three discomfort levels. Mild corresponds to approximately 0.3mg/kg per dose. Moderate approaches 1mg/kg. Severe reaches 1.3mg/kg per dose, with twice-daily administration bringing the total daily intake toward the 2.9mg/kg target for dogs with significant chronic conditions.

Dog Weight Mild Discomfort Moderate Discomfort Severe Discomfort
10 lbs (4.5 kg) 3 mg 10 mg 13 mg
20 lbs (9 kg) 7 mg 20 mg 26 mg
30 lbs (13.6 kg) 10 mg 30 mg 40 mg
40 lbs (18 kg) 13 mg 40 mg 53 mg
60 lbs (27 kg) 20 mg 60 mg 79 mg
75 lbs (34 kg) 25 mg 75 mg 99 mg
100 lbs (45 kg) 33 mg 100 mg 133 mg
Start Low Begin at mild. Titrate upward every 2 weeks based on observed response.
30–45 Min Administer before anticipated stressors for acute anxiety support.
Ask Your Vet Required if your dog is on phenobarbital, NSAIDs, or immunosuppressants.

Drug interaction: CBD inhibits cytochrome P450 enzymes, raising plasma concentrations of concurrently administered medications including phenobarbital and potassium bromide. Dogs on anticonvulsants, NSAIDs, or immunosuppressants require veterinary supervision before starting any CBD protocol. CBD is not contraindicated, but conventional drug doses may need adjustment.

Tincture or Treats: Choosing the Right Format

Both formats use the same solventless rosin extraction standard and are batch-tested by ISO 17025-accredited third-party laboratories. The choice between them is clinical, not preferential.

VetsGrade Relief+ Tincture 2000mg Relief+ Tincture

2000mg Full Spectrum | 33mg/mL

Format: Liquid dropper, precise volume control

Best for: Dogs over 50 lbs, cats, severe discomfort, arthritis, chronic conditions, flexible dose titration

Administration: Direct oral or mixed with food. Fat-containing food enhances absorption.

Onset: 30 to 45 minutes oral. Chronic effect builds over 2 to 4 weeks.

VetsGrade Bosco's Recipe Treats 30mg Bosco's Recipe Treats

30mg per treat | 25 treats/pkg

Format: Pre-measured crispy treat, no mess, portable

Best for: Dogs under 50 lbs, mild to moderate discomfort, travel anxiety, fireworks, training

Administration: 1 treat per 25 lbs body weight. Maximum 5 treats per day.

Carrier lipids: Coconut oil and extra virgin olive oil enhance cannabinoid absorption within the treat itself.

The tincture serves conditions requiring precise dose adjustment. A 68-lb dog with osteoarthritis titrating upward needs the granularity a dropper provides, because a treat delivering 30mg fixed increments cannot split that difference. The treat format serves conditions where compliance determines whether the dose happens at all. A dog that refuses a tincture will accept a treat. Delivery architecture determines bioavailability before anything else does.

What Is in Bosco's Recipe

Every ingredient serves a function. The formulation is a whole-food matrix designed to support cannabinoid absorption, palatability, and nutritional density simultaneously.

Ingredient Function
Sweet Potato* Prebiotic fiber, beta-carotene, digestive support
Rolled Oats* Soluble fiber, slow-release energy, palatability
Coconut Oil* Medium-chain triglycerides, primary lipid carrier for cannabinoid absorption
Cinnamon Oil* Anti-inflammatory, antimicrobial, palatability
Sunflower Lecithin* Phospholipid emulsifier, increases cannabinoid particle surface area for absorption
Clover Honey* Natural palatability, antimicrobial properties
Mixed Tocopherols (Vitamin E) Antioxidant preservation of cannabinoids and lipids
Extra Virgin Olive Oil* Oleic acid lipid carrier, secondary absorption enhancer
Solventless Full Spectrum CBD Rosin* Active cannabinoid delivery, full phytochemical profile preserved

*Denotes Organic Origin. No added salt, sugar, artificial colors, flavors, or preservatives.

Reading a Certificate of Analysis

A COA is the only document that tells you what is actually in the product. Not what the manufacturer claims, but what an independent laboratory confirmed. Those two numbers are not always the same.

Four standards determine whether a COA is valid. It must be batch-specific, corresponding to the exact production run in your hand. It must be issued by an ISO 17025-accredited third-party laboratory whose testing methodology has been independently validated. It must be publicly searchable by Batch ID without a contact form submission. A COA behind a login wall is a liability shield, not a transparency document. The fourth standard is the most commonly overlooked: a COA showing only CBD content is incomplete.

A full panel for a full spectrum product must include cannabinoid potency across CBD, CBDA, CBG, CBC, THC, and THCA, plus a terpene panel, heavy metals, pesticides, residual solvents, and microbials. The CBDA percentage and terpene panel are the numbers that confirm whether the entourage effect is pharmacologically present. A product with no detectable CBDA and no terpene panel is not delivering full spectrum pharmacology regardless of what the label says.

Food, Timing, and Absorption

Lipid-rich meals increase oral cannabinoid bioavailability by providing the fat matrix cannabinoids require for efficient intestinal uptake through the lymphatic system. A dose given to a fasted dog delivers meaningfully less active cannabinoid to systemic circulation than the same dose given with food. This is the difference between a dose that reaches therapeutic plasma concentration and one that does not.

Bosco's Recipe addresses this within the formulation. The coconut oil and olive oil content creates the lipid absorption environment internally, without requiring coordination with a meal. The tincture requires more deliberate administration, and adding it to food rather than dropping it into an empty mouth produces better outcomes.

Timing logic differs between acute and chronic conditions. For anxiety associated with travel, fireworks, or veterinary visits, administration 30 to 45 minutes before the anticipated stressor allows plasma concentration to peak when it is needed. For chronic conditions, including joint inflammation, mobility impairment, and seizure management, consistent twice-daily dosing at the same time each day maintains steady-state plasma concentration. Missing doses disrupts that steady state and extends the time to therapeutic effect.

Feline Dosing: A Different Pharmacology

Cats metabolize cannabinoids more slowly than dogs. Lower hepatic glucuronidation capacity means cannabinoids accumulate with repeated dosing at rates that do not occur in dogs at equivalent mg/kg levels. CBD elimination half-life in cats reaches up to 17.1 hours, with CBD detectable in plasma up to 48 hours post-dose, and inter-individual variance is substantial.[6]

Once-daily administration at the low end of the weight-based chart is the appropriate starting point. Allow a minimum of two weeks at each dose level before any upward adjustment. The dropper format allows the precise low-volume dosing feline patients require. Bosco's Recipe treats are formulated for dogs.

Find Your Pet's Starting Dose

Use the dosing calculator to find the precise starting point for your dog or cat based on weight and condition severity.

Use the Dosing Calculator Shop Products

Frequently Asked Questions

The peer-reviewed canine literature documents consistent therapeutic response between 2mg/kg and 4mg/kg twice daily. 2.9mg/kg sits above the confirmed efficacy floor, accounts for individual pharmacokinetic variability in CYP450 enzyme clearance rates, and takes advantage of the CBDA bioavailability advantage preserved in solventless full spectrum products. It is a calculated midpoint within a documented therapeutic window, not a round number chosen for convenience.

Acute effects such as anxiety reduction are typically observable within 30 to 45 minutes. Chronic conditions require two to four weeks of consistent twice-daily dosing before measurable improvement appears. The mechanism for chronic conditions operates through receptor modulation and inflammatory pathway changes that require sustained cannabinoid exposure to produce measurable change. Do not assess efficacy after a single dose.

The safety margin for CBD in dogs is wide. Transient sedation and mild gastrointestinal upset are the most commonly reported effects at doses above the therapeutic range, with no serious adverse events documented at therapeutic doses.[7] The clinical concern is not acute toxicity. It is the drug interaction profile. Dogs on phenobarbital, potassium bromide, NSAIDs, or immunosuppressants require veterinary supervision regardless of dose level.

CBDA in full spectrum extract reaches peak plasma concentration 3.4 times higher than CBD isolate at equivalent labeled doses, with an AUC nearly three times greater.[5] Three of four canine osteoarthritis trials using full spectrum formulations showed significant positive outcomes; the two using isolate showed the weakest effect profiles.[4] The entourage effect, the pharmacological synergy between cannabinoids and terpenes, is the mechanism responsible.

Yes. Lipid-rich meals significantly increase oral cannabinoid bioavailability through the lymphatic system. A dose given to a fasted dog delivers meaningfully less active cannabinoid to systemic circulation than the same dose given with food. Bosco's Recipe treats address this within the formulation through coconut oil and olive oil content. The tincture should be added to food rather than administered to a fasted animal.

A valid COA is batch-specific, issued by an ISO 17025-accredited third-party laboratory, and publicly searchable by Batch ID without a contact form submission. The full panel must include cannabinoid potency across CBD, CBDA, CBG, CBC, THC, and THCA, plus a terpene panel, heavy metals, pesticides, residual solvents, and microbials. A COA showing only CBD content cannot confirm whether the entourage effect is pharmacologically present.

Solventless extraction uses mechanical pressure and heat rather than chemical solvents. This preserves CBDA, terpenes, and flavonoids that solvent-based processing and high-heat decarboxylation destroy. CBDA is converted to CBD through heat, meaning any extraction method involving high heat eliminates the compound that absorbs 3.4 times more efficiently than CBD at equivalent doses. Solventless is the only method that preserves CBDA at pharmacologically relevant concentrations.

Start at the low end of the weight-based chart, use once-daily administration initially, and allow a minimum of two weeks at each dose level before any upward adjustment. CBD elimination half-life in cats reaches up to 17.1 hours, with CBD detectable in plasma up to 48 hours post-dose.[6] Inter-individual variance is substantial, so titrate slowly and observe carefully before increasing.

References

1 Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, Brown H, Berthelsen ES, Wakshlag JJ. Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Frontiers in Veterinary Science. 2018;5:165. https://doi.org/10.3389/fvets.2018.00165
2 Escobar Torres B, Silva Elgueta MT, Navarro Soto A, Suárez Araya S, Sandoval Contreras M, Arrau Barra S. Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum Oral Cannabis sativa Oil Extract, Standardized Based on CBD-A, CBD and THC-A, THC in Canines with Chronic Osteoarthritis. Animals. 2026;16:900. https://doi.org/10.3390/ani16060900
3 McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association. 2019;254(11):1301–1308. https://doi.org/10.2460/javma.254.11.1301
4 Yeung T, Uquillas F. Does oral cannabidiol oil in adjunct to pain medications help reduce pain and improve locomotion in dogs with osteoarthritis? Veterinary Evidence. 2025;10(1). https://doi.org/10.18849/ve.v10i1.701
5 Wang TC, Wakshlag JJ, Lyubimov A, Zakharov A, Gomez B, Schwark W, Trottier NL. Limited 12-hour pharmacokinetic assessment of CBD and CBDA isolates compared to their full-spectrum extracts in healthy adult beagles. Frontiers in Veterinary Science. 2025;12:1639846. https://doi.org/10.3389/fvets.2025.1639846
6 Lyons C, McEwan K, Munn-Patterson M, Vuong S, Alcorn J, Chicoine A. Pharmacokinetic of two oral doses of a 1:20 THC:CBD cannabis herbal extract in cats. Frontiers in Veterinary Science. 2024;11:1352495. https://doi.org/10.3389/fvets.2024.1352495
7 Bookout W, Dziwenka M, Valm K, Kovacs-Nolan J. Safety study of cannabidiol products in healthy dogs. Frontiers in Veterinary Science. 2024;11:1349590. https://doi.org/10.3389/fvets.2024.1349590

Disclaimer: This article is intended for informational and educational purposes only and does not constitute veterinary medical advice, diagnosis, or treatment. The information presented is based on published peer-reviewed research and is not a substitute for professional veterinary consultation. Full spectrum CBD products have not been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition in animals. Individual results may vary. Dogs and cats with preexisting medical conditions or concurrent medications require veterinary supervision before initiating any CBD protocol. CYP450 enzyme inhibition by cannabinoids may alter plasma concentrations of concurrently administered medications. Disclose all supplement use to your veterinarian.